A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

NCT06859268 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication retatrutide can help people with obesity maintain weight loss.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 643 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-03 · est. completion 2028-04

Where 53 sites · Canada, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06859268 ↗

Description as written by the study sponsor.

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06859268 ↗